Species differences in plasma protein binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease inhibitor nirmatrelvir

References

• Banker MJ, Clark TH, Williams JA. 2003. Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci. 92(5):967–974.
   PubMed Web of Science ®Google Scholar
• Bohnert T, Gan L-S. 2013. Plasma protein binding: from discovery to development. J Pharm Sci. 102(9):2953–2994.
   PubMed Web of Science ®Google Scholar
• Brown AM. 2005. HERG block, QT liability and sudden cardiac death. Novartis Found Symp. 266:118–131.
   PubMedGoogle Scholar
• Bteich M. 2019. An overview of albumin and alpha-1-acid glycoprotein main characteristics: highlighting the roles of amino acids in binding kinetics and molecular interactions. Heliyon. 5(11):e02879.
   PubMed Web of Science ®Google Scholar
• Ceciliani F, Pocacqua V. 2007. The acute phase protein alpha1-acid glycoprotein: a model for altered glycosylation during diseases. CPPS. 8(1):91–108.
   Web of Science ®Google Scholar
• Chamouard J, Barre J, Urien S, Houin G, Tillement JP. 1985. Diclofenac binding to albumin and lipoproteins in human serum. Biochem Pharmacol. 34(10):1695–1700.
   PubMed Web of Science ®Google Scholar
• Colclough N, Ruston L, Wood JM, Macfaul PA. 2014. Species differences in drug plasma protein binding. Med Chem Commun. 5(7):963–967.
   Web of Science ®Google Scholar
• Dale O, Nilsen OG. 1984. Differences in the serum protein binding of prazosin in man and rat. Biochem Pharmacol. 33(11):1719–1724.
   PubMed Web of Science ®Google Scholar
• Denissen JF, Grabowski BA, Johnson MK, Buko AM, Kempf DJ, Thomas SB, Surber BW. 1997. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab Dispos. 25(4):489–501.
   PubMed Web of Science ®Google Scholar
• Dente L, Ciliberto G, Cortese R. 1985. Structure of the human alpha-1-acid glycoprotein gene: sequence homology with other human acute phase protein genes. Nucl Acids Res. 13(11):3941–3952.
   PubMed Web of Science ®Google Scholar
• Di L. 2021. An update on the importance of plasma protein binding in drug discovery and development. Expert Opin Drug Discov. 16(12):1453–1465.
   PubMed Web of Science ®Google Scholar
• Eng H, Dantonio AL, Kadar EP, Obach RS, Di L, Lin J, Patel NC, Boras B, Walker GS, Novak JJ, et al. 2022. Disposition of PF-07321332 (Nirmatrelvir), an orally bioavailable inhibitor of SARS-CoV-2 3CL protease, across animals and humans. Drug Metab Dispos. 50(5):576–590.
   PubMed Web of Science ®Google Scholar
• Fournier T, Medjoubi NN, Porquet D. 2000. Alpha-1-acid glycoprotein. Biochim Biophys Acta. 1482(1-2):157–171.
   PubMed Web of Science ®Google Scholar
• Ghuman J, Zunszain PA, Petitpas I, Bhattacharya AA, Otagiri M, Curry S. 2005. Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol. 353(1):38–52.
   PubMed Web of Science ®Google Scholar
• Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, et al. 2022. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N Engl J Med. 386(15):1397–1408.
   PubMed Web of Science ®Google Scholar
• Hassan M, Azzazy E, Christenson RH. 1997. All about albumin: biochemistry, genetics, and medical applications. Clin Chem. 43(10):2014a–2015.
   Google Scholar
• Huang RYC, Hudgens JW. 2013. Effects of desialylation on human α1-acid glycoprotein–ligand interactions. Biochemistry. 52(40):7127–7136.
   PubMed Web of Science ®Google Scholar
• Kimhofer T, Lodge S, Whiley L, Gray N, Loo RL, Lawler NG, Nitschke P, Bong S-H, Morrison DL, Begum S, et al. 2020. Integrative modeling of quantitative plasma lipoprotein, metabolic, and amino acid data reveals a multiorgan pathological signature of SARS-CoV-2 infection. J. Proteome Res. 19(11):4442–4454.
   PubMed Web of Science ®Google Scholar
• Kumar GN, Jayanti VK, Johnson MK, Uchic J, Thomas S, Lee RD, Grabowski BA, Sham HL, Kempf DJ, Denissen JF, et al. 2004. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans. Pharm Res. 21(9):1622–1630.
   PubMed Web of Science ®Google Scholar
• Kuribayashi T, Shimizu M, Shimada T, Honjyo T, Yamamoto Y, Kuba K, Yamamoto S. 2003. Alpha 1-Acid Glycoprotein (AAG) levels in healthy and pregrant beagle dogs. Exp. Anim. 52(5):377–381.
   PubMed Web of Science ®Google Scholar
• Matsuzawa T, Nomura M, Unno T. 1993. Clinical pathology reference ranges of laboratory animals. J Vet Med Sci. 55(3):351–362.
   PubMed Web of Science ®Google Scholar
• Melillo A. 2007. Rabbit clinical pathology. J Exot Pet Med. 16(3):135–145.
   PubMed Web of Science ®Google Scholar
• Nishi K, Ono T, Nakamura T, Fukunaga N, Izumi M, Watanabe H, Suenaga A, Maruyama T, Yamagata Y, Curry S, et al. 2011. Structural insights into differences in drug-binding selectivity between two forms of human alpha1-acid glycoprotein genetic variants, the A and F1*S forms. J Biol Chem. 286(16):14427–14434.
   PubMed Web of Science ®Google Scholar
• Owen DR, Allerton CMN, Anderson AS, Aschenbrenner L, Avery M, Berritt S, Boras B, Cardin RD, Carlo A, Coffman KJ, et al. 2021. An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19. Science. 374(6575):1586–1593.
   PubMed Web of Science ®Google Scholar
• Primozic S, McNamara PJ. 1985. Effect of the Sialylation State of Alpha-1 Acid Glycoprotein on Propanolol Binding. J Pharm Sci. 74(4):473–475.
   PubMed Web of Science ®Google Scholar
• Ray BK, Ray A. 1991. Molecular cloning and nucleotide sequence of complementary DNA encoding rabbit alpha 1-acid glycoprotein. Biochem Biophys Res Commun. 178(2):507–513.
   PubMed Web of Science ®Google Scholar
• Reddy MB, Morcos PN, Le Pogam S, Ou Y, Frank K, Lave T, Smith P. 2012. Pharmacokinetic/Pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors. Antimicrob Agents Chemother. 56(6):3144–3156.
   PubMed Web of Science ®Google Scholar
• Sathish JG, Bhatt S, DaSilva JK, Flynn D, Jenkinson S, Kalgutkar AS, Liu M, Manickam B, Pinkstaff J, Reagan WJ, et al. 2022. Comprehensive Nonclinical safety assessment of nirmatrelvir supporting timely development of the SARS-COV-2 antiviral therapeutic, Paxlovid™. Int J Toxicol. 0(0):1–15.
   Google Scholar
• Schön A, del Mar Ingaramo M, Freire E. 2003. The binding of HIV-1 protease inhibitors to human serum proteins. Biophys Chem. 105(2-3):221–230.
   PubMed Web of Science ®Google Scholar
• Schönfeld DL, Ravelli RBG, Mueller U, Skerra A. 2008. The 1.8-A crystal sturcture of alpha1-acid glycoprotein (Orosomucoid) solved by UV RIP reveals the broad drug-binding activity of this human plasma lipocalin. J Mol Biol. 384(2):393–405.
   PubMed Web of Science ®Google Scholar
• Shtyrya YA, Mochalova LV, Bovin NV. 2009. Influenza virus neuraminidase: structure and function. Acta Naturae. 1(2):26–32.
   PubMed Web of Science ®Google Scholar
• Singh RSP, Toussi SS, Hackman F, Chan PL, Rao R, Allen R, Van Eyck L, Pawlak S, Kadar EP, Clark F, et al. 2022. Innovative randomized phase 1 study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of. Clin Pharma and Therapeutics. 112(1):101–111.
   PubMed Web of Science ®Google Scholar
• Smith SA, Waters NJ. 2019. Pharmacokinetic and pharmacodynamic considerations for drugs binding to alpha-1-acid glycoprotein. Pharm Res. 36(2):30.
   Web of Science ®Google Scholar
• Stanke‐Labesque F, Concordet D, Djerada Z, Bouchet S, Solas C, Mériglier E, Bonnet F, Mourvillier B, Ruiz S, Martin‐Blondel G, et al. 2021. Neglecting plasma protein binding in COVID‐19 patients leads to a wrong interpretation of lopinavir overexposure. Clin. Pharmacol. Ther. 109(4):1030–1033.
   PubMed Web of Science ®Google Scholar
• Vella-Brincat JWA, Begg EJ, Kirkpatrick CMJ, Zhang M, Chambers ST, Gallagher K. 2007. Protein binding of cefazolin is saturable in vivo both between and within patients. Br J Clin Pharmacol. 63(6):753–757.
   PubMed Web of Science ®Google Scholar
• Verkhivker GM, Bouzida D, Gehlhaar DK, Rejto PA, Arthurs S, Colson AB, Freer ST, Larson V, Luty BA, Marrone T, et al. 2000. Deciphering common failures in molecular docking of ligand-protein complexes. J Comput Aided Mol Des. 14(8):731–751.
   PubMed Web of Science ®Google Scholar
• Wang Z-m, Ho JX, Ruble JR, Rose J, Rüker F, Ellenburg M, Murphy R, Click J, Soistman E, Wilkerson L, et al. 2013. Structural studies of several clinically important oncology drugs in complex with human serum albumin. Biochim Biophys Acta. 1830(12):5356–5374.
   PubMed Web of Science ®Google Scholar
• Wang J, Li-Chan XX, Atherton J, Deng L, Espina R, Yu L, Horwatt P, Ross S, Lockhead S, Ahmad S, et al. 2010. Characterization of HKI-272 Covalent Binding to Human Serum Albumin. Drug Metab Dispos. 38(7):1083–1093.
   PubMed Web of Science ®Google Scholar
• Wong A, Hsia J. 1983. In vitro binding of propanolol and progesterone to native and desialylated human orosomucoid. Can J Biochem Cell Biol. 61(10):1114–1116.
   PubMedGoogle Scholar
• Yamada K, Yokomaku K, Kureishi M, Akiyama M, Kihira K, Komatsu T. 2016. Artificial Blood for Dogs. Sci Rep. 6(1):36782.
   PubMed Web of Science ®Google Scholar
• Zhu M, Zhang D, Zhang H, Shyu WC. 2009. Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations. Biopharm. Drug Dispos. 30(4):163–184.
   PubMed Web of Science ®Google Scholar
• Zielinski K, Sekula B, Anna B, Szymczak I. 2020. Structural investigations of stereoselective profen binding by equine and leporine serum albumins. Chirality. 32(3):334–344.
   PubMed Web of Science ®Google Scholar
• Zini R, Morin D, Jouenne P, Tillement JP. 1988. Cicletanine binding to human plasma proteins and erythrocytes, a particular HSA-drug interaction. Life Sci. 43(25):2103–2115.
   PubMed Web of Science ®Google Scholar